Acesso livre
Acesso livre

Infectologia

Diretriz | Abdome agudo em pacientes imunocomprometidos.

16 Ago, 2021 | 11:53h

Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines – World Journal of Emergency Surgery

Perspectiva | Como a pandemia terminará.

13 Ago, 2021 | 12:29h

How the pandemic now ends – The Atlantic

 

Comentário no Twitter (fio – clique para saber mais)

 

Doença de Kawasaki e síndrome inflamatória multissistêmica em crianças: uma visão geral e comparação.

13 Ago, 2021 | 12:27h

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison – American Family Physician

Conteúdos relacionados:

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Opinião | A fluvoxamina poderia ser nosso primeiro tratamento efetivo, barato e amplamente disponível para COVID-19?

13 Ago, 2021 | 12:26h

Could This Be Our First Effective, Inexpensive, Widely Available Outpatient Treatment for COVID-19? – HIV and ID Observations

Conteúdo relacionado: Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Como pessoas vacinadas disseminam a variante Delta? O que diz a ciência.

13 Ago, 2021 | 12:24h

How do vaccinated people spread Delta? What the science says – Nature

Como a COVID-19 mudará o tratamento de outras infecções virais respiratórias.

13 Ago, 2021 | 12:21h

How COVID-19 will change the management of other respiratory viral infections – Intensive Care Medicine

 

Comentário no Twitter

 

Opinião | Hora de uma abordagem inteligente das doses de reforço.

13 Ago, 2021 | 12:20h

Time for a Smart Approach to Boosters – Think Global Health

Opinião | Disponibilização das vacinas para outros países antes de fazer uma vacinação doméstica de reforço.

13 Ago, 2021 | 12:18h

Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations – JAMA

Resposta de anticorpos à vacinação da COVID-19 em adultos com doença hematológica maligna.

13 Ago, 2021 | 12:17h

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease – JAMA Oncology

 

Comentário no Twitter

 

Estudo randomizado | Avaliação da vacina de mRNA da Moderna em adolescentes.

12 Ago, 2021 | 12:30h

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine

Conteúdos relacionados:

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

RCT: Pfizer-BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – mainly transient mild-to-moderate reactogenicity was frequently observed, such as injection-site pain (in 79 to 86% of participants), fatigue (in 60 to 66%), and headache (in 55 to 65%).

 

Comentários no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.